RMD Stock Set to Gain From FDA Clearance of AI-Enabled Smart Comfort

Resmed gains FDA's nod for Smart Comfort, an AI-driven CPAP tool boosting sleep therapy personalization and adherence.

Zacks Investment Research • Dec 9, 2025

Resmed Receives FDA Clearance for Personalized Therapy Comfort Settings, to be Marketed as Smart Comfort, an AI-Enabled, Digital Medical Device That Helps Personalize CPAP Therapy

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has received U.S. Food and Drug Administration (FDA) clearance for Personalized Therapy Comfort Settings (PTCS), to be marketed as Smart Comfort. Smart Comfort is the first FDA-cleared AI-enabled medical device that recommends personalized comfort settings to help people with obstructive sleep apnea (OSA) start and stay on CPAP therapy.

GlobeNewsWire • Dec 8, 2025

Top 50 High-Quality Dividend Growth Stocks For December 2025

I track a custom universe of 50 high-quality dividend growth stocks to identify timely, attractive investment opportunities based on valuation and forward return potential. 28 of these stocks currently offer estimated future returns of at least 10%, with 18 appearing potentially undervalued per my Free Cash Flow model. Top-ranked names like ResMed, Mastercard, and MSCI combine strong projected EPS growth with reasonable valuations.

Seeking Alpha • Dec 9, 2025

Should You Continue to Hold RMD Stock in Your Portfolio?

Resmed sees strong mask sales, strategic acquisitions and international expansion despite macro and competitive challenges.

Zacks Investment Research • Dec 3, 2025

IDEXX Laboratories Vs ResMed: Which Stock Could Rally?

IDEXX Laboratories' (IDXX) recent jump has investors questioning whether it's still the best bet—or if a stronger opportunity exists elsewhere. A closer look at its key competitor suggests there may be a clearer winner.

Forbes • Nov 24, 2025

ResMed: Safe Bet For A Recession Environment

ResMed is rated a buy due to strong fundamentals, expanding margins, robust cash flow, and resilience in recessionary environments. RMD's steady topline growth, high profitability, low debt, and significant cash reserves position it favorably for investors who want to protect their portfolio for a recession. RMD's operational efficiency and cash balance support continued dividend growth and potential buybacks.

Seeking Alpha • Nov 17, 2025

Could GLP-1 Drugs Make ResMed's CPAP Machines Obsolete?

GLP-1 drugs pose an existential threat to CPAP-makers. ResMed is currently experiencing temporary tailwinds before potential long-term headwinds.

The Motley Fool • Nov 12, 2025

These Analysts Revise Their Forecasts On ResMed Following Q1 Results

ResMed Inc. (NYSE:RMD) reported better-than-expected earnings for the first quarter on Thursday.

Benzinga • Oct 31, 2025

Resmed Stock Up on Q1 Earnings & Revenue Beat, Margins Expand

RMD's Q1 earnings and revenues top estimates as solid device and mask sales lift margins and boost investor confidence.

Zacks Investment Research • Oct 31, 2025

ResMed Inc. (RMD) Q1 2026 Earnings Call Transcript

ResMed Inc. ( RMD ) Q1 2026 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Sallilyn Schwartz - Chief Investor Relations Officer Michael Farrell - CEO & Chairman Brett Sandercock - Chief Financial Officer Conference Call Participants Davinthra Thillainathan - Goldman Sachs Group, Inc., Research Division Laura Sutcliffe - Citigroup Inc. Exchange Research Saul Hadassin - Barrenjoey Markets Pty Limited, Research Division Lyanne Harrison - BofA Securities, Research Division Steven Wheen - Jarden Limited, Research Division David Bailey - Morgan Stanley, Research Division Brett Fishbin - KeyBanc Capital Markets Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Dan Hurren - MST Financial Services Pty Limited, Research Division Presentation Operator Hello, and welcome to the Q1 Fiscal Year 2026 ResMed Earnings Conference Call. My name is Kevin.

Seeking Alpha • Oct 31, 2025